Table 3.
Clinical characteristics of patients with hypophysitis following CTLA4 blockade
| Hypophysitis | n=19 (%) |
|---|---|
| Gender | |
| Males, n=134 total | 11 of 134 (8) |
| Females, n=77 total | 8 of 77 (10) |
| Dose of ipilimumab | |
| 3 mg/kg (n=119) | 10 (8) |
| 10 mg/kg (n=92) | 9 (10) |
| Median time to onset of hypophysitis after the first dose of ipilimumab | 4 months |
| Hormone axes involved (confirmed and/or suspected) | |
| Corticotrophs (could not be assessed in three patients) | 16 |
| Thyrotrophs (definite and/or possible; could not be assessed in one patient) | 11 |
| Gonadotrophs (could not be assessed in six patients) | 5 |
| Definite preservation of corticotroph secretion | 0 |
| MRI brain/sella completed | 12 |
| Normal/near normal | 3 (25) |
| Abnormal | 9 (75) |
| Received high-dose steroids at diagnosis | 18 (95) |
| Recovery of hormone function | |
| Not assessed | 5 |
| No recovery of axis/axes | 9 |
| Recovery of ACTH secretion | 3 |
| Recovery of TSH secretion | 0 |
| Recovery of LH and FSH secretion | 2 |
| Developed additional non-dermatological irAEs | 8 |
| Overall status at last follow-up | |
| Alive | 11 |
| Dead | 7 |
| Unknown, lost to follow-up | 1 |